Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Fineline Cube Dec 29, 2025
Company Drug

Hengrui NMPA Approves Four Clinical Trials Advancing Oncology and Metabolic Pipeline

Fineline Cube Dec 15, 2025

Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...

Company Drug

GSK’s Nucala Wins CHMP Nod for COPD in Europe

Fineline Cube Dec 15, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency’s Committee for...

Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025

Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced a definitive agreement to acquire Arthrosi Therapeutics,...

Company Drug

Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity

Fineline Cube Dec 15, 2025

Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s Committee for Medicinal Products...

Company Drug

Innovent’s Mazdutide Wins Macau Approval for Weight Management

Fineline Cube Dec 15, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that mazdutide received marketing approval from Macau’s drug regulatory...

Company Deals

Kyinno Biotechnology Closes RMB 250M Series B for Bispecific Antibody Pipeline

Fineline Cube Dec 15, 2025

Kyinno Biotechnology, a China‑based biotech company, announced the completion of its Series B financing round...

Company Deals

Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing

Fineline Cube Dec 15, 2025

Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...

Company Drug

Akeso’s Cadonilimab Wins FDA Nod for Global Phase 3 Gastric Cancer Study

Fineline Cube Dec 15, 2025

Akeso Biopharma (HKG: 9926) announced that the U.S. FDA approved cadonilimab in combination with chemotherapy...

Policy / Regulatory

China Healthcare Fund Settlement Reform Targets 3% Ratio by 2028

Fineline Cube Dec 15, 2025

The National Healthcare Security Administration (NHSA) released a notice to optimize healthcare fund settlement management,...

Company Drug

Junshi Biosciences Wins FDA Nod for EGFR/HER3 Bispecific ADC in Solid Tumors

Fineline Cube Dec 15, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and...

Company Drug

Henlius Serplulimab NDA Wins Priority Review for Gastric Cancer as Adjuvant Therapy

Fineline Cube Dec 15, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the NMPA accepted its New Drug Application...

Company Deals

Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline

Fineline Cube Dec 15, 2025

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. released its prospectus for a Hong Kong Stock Exchange listing...

Policy / Regulatory

China Unveils Elderly Nursing Plan to Boost 90% Nurse Coverage by 2027

Fineline Cube Dec 15, 2025

China’s National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Administration of Traditional Chinese...

Company Drug

Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis

Fineline Cube Dec 15, 2025

Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients...

Company Drug

Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market

Fineline Cube Dec 15, 2025

Suzhou Huadao Biological Pharmacy Co., Ltd. officially submitted a Marketing Authorization Application (MAA) to the...

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Fineline Cube Dec 14, 2025

Peijia Medical Limited (HKG: 9996) announced that China’s National Medical Products Administration (NMPA) approved the...

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025

Hasten Biopharmaceutical Co., Ltd. and Everest Medicines Limited (HKG: 1952) announced two strategic agreements: a...

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Fineline Cube Dec 14, 2025

Eli Lilly & Co. (NYSE: LLY) announced positive topline results from the Phase 3 TRIUMPH‑4...

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Fineline Cube Dec 14, 2025

Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that its Class 1 innovative drug, Pixavir...

Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Fineline Cube Dec 14, 2025

InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a...

Posts pagination

1 … 4 5 6 … 601

Recent updates

  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
  • Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer
  • Wantai Biological Secures NMPA Approval for First Oral HIV Self-Test Kit in China
  • Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Company Drug

Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer

Company Medical Device

Wantai Biological Secures NMPA Approval for First Oral HIV Self-Test Kit in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.